Corporate ActionMay 5, 2026, 02:03 AM
Abivax Repurchases $90M Royalty Certificates; Prices $45M ADS Offering
AI Summary
Abivax announced the repurchase of all outstanding Royalty Certificates for $90 million, aiming to strengthen its balance sheet and simplify its capital structure. The repurchase will be partially funded by a $45 million cash payment and a $45 million offering of American Depositary Shares (ADSs) to the certificate holders. This transaction is expected to reduce the royalty overhang and maintain the company's cash runway into Q4 2027.
Key Highlights
- Abivax repurchased all outstanding Royalty Certificates for $90 million.
- $45 million of the purchase price will be paid in cash.
- $45 million will be paid through an offering of 403,347 ADSs to the holders.
- The offering price for the ADSs is $111.57 per ADS.
- The transaction will result in approximately 0.5% dilution of the share capital.
- Cash runway remains into Q4 2027, unchanged after the repurchase.
- Cash, cash equivalents, and short-term investments were €530.4 million as of December 31, 2025.